SALT LAKE CITY, Jan. 18, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, Gordon Silver Limited and Verity ...

SHANGHAI, Sept. 24, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK), a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced today ...

DURHAM, N.C., September 24, 2025--(BUSINESS WIRE)--Cree LED, a Penguin Solutions brand (Nasdaq: PENG), and ADJ Products, LLC (ADJ) today announced that they have reached a mutually beneficial ...

- Upon closing, Arrowhead will receive an upfront payment of $200 million - Novartis will receive an exclusive worldwide license to ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy for the ...

KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most ...

Collaboration highlights Hengrui Pharma's successful use of the NewCo model to achieve another out-licensing deal Agreement grants Braveheart Bio exclusive global rights to develop, manufacture and ...